Risk factor
Very vulnerable to price shocks
Profitability factor
Greatly overvalued vs peers
About
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of IONS is 89 and suggests 10% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation su
Buy
Sell